Fragment HGH 176-191
HGH 176-191, also called AOD9604, is a fragment of growth hormone that controls the release and burning of fats, but without affecting the growth of internal organs and blood sugar.
The HGH fragment 176-191, is a modified form of the amino acid chain 176-191 in the C-terminal area of human growth hormone. It was discovered at Monash University in Australia. The researchers here found that the lipolytic (burning fat) properties of growth hormone are controlled by a small portion at the end of the molecule. This region, which is composed of amino acids 176-191, represents less than 10% of the mass of the HGH molecule and has no effect on growth and insulin.
It works by mimicking the way human growth hormone regulates fat metabolism, but without the adverse effects on blood glucose or internal organ growth, as is the case with HGH. Like HGH, fragment 176-191 stimulates lipolysis (fat burning) and inhibits lipogenesis (creation of new fat deposits). Does not affect appetite.
In laboratory tests, HGH fragment 176-191 released fatty acids especially from obese cells, normal cells remaining relatively unaffected, stopped fat accumulation in all fat cells, and improved the burning of fatty acids released from fat cells. In laboratory mouse tests, he reduced body fat in obese mice, without altering their diet and without registering internal organ growth or other unwanted side effects that occur when using synthetic growth hormone.
It seems that the HGH fragment 176-191 mainly reduces abdominal fat, especially visceral fat. It also has a slight effect of increasing muscle mass, but it remains in particular a substance used for fat burning. It can also improve lipid profile (lowers bad cholesterol and raises good cholesterol). Until now, studies lead to the conclusion that in the future it can be used as a medicine for the treatment of obesity, with much reduced side effects compared to synthetic growth hormone.
Possible side effects are swelling of the hands and headaches, but there is not enough data to say exactly what harmful effects it may have in the long term. It does not influence the production of IGF, or other hormones.
The administration is done daily, by subcutaneous injections, with insulin needles. The doses are between 150 mcg and 250 mcg, but there are people who increase the dose up to 500 mcg / day. It is found in the form of powder, which dissolves in bacteriostatic water.
It is good that the HGH fragment 176-191 be administered either before cardio or before bedtime.
As this preparation works by releasing the fat stored in the blood stream, it is good that nothing is eaten around the injection, so that the body uses the fat released for energy.
Another strategy is to do the injection in the morning, then do a cardio session, and wait a few hours until you get the first meal, consisting largely of protein. If you do your injection in the evening, eat at least 3 hours before bedtime, also a meal high in protein and low in fat and carbohydrates.